Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546280 | 0.93 | KDR (0.53) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL5438836 | 0.92 | KDR (0.54) | KDRFGFR1BRAF | |
| SCHEMBL5426983 | 0.89 | KDR (0.53) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL546211 | 0.87 | KDR (0.68) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL10199786 | 0.86 | KDR (0.51) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL545944 | 0.83 | BRAF (0.53) | KDRBRAFHTR2AHTR2CLTA4H | |
| SCHEMBL546655 | 0.83 | KDR (0.49) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL546100 | 0.83 | KDR (0.49) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL5425709 | 0.80 | KDR (0.55) | KDRFGFR1BRAFHTR2AHTR2C | |
| SCHEMBL5425786 | 0.80 | KDR (0.48) | KDRFGFR1BRAFHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | KDR 1264/4885FGFR1 580/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.